COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's plant-based drug crofelemer granted Orphan Drug Designation for MVID and SBS, with proof-of-concept studies planned for 2024. Napo sponsors Elite Ped-GI Congress panel discussion on rare digestive disorders -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs
